Eli Lilly & Co.

Address
1 Lilly Corporate Center

Sponsor Overview

assignment
135
sponsored trials
science
19
molecules
location_city
1693
research centres
public
25
countries
person_search
2920
investigators

Specializations

Oncology and Haematologic Malignancies

Clinical research includes breast cancer, non-small cell lung cancer, prostate cancer, colorectal cancer, pancreatic cancer, ovarian cancer, urothelial carcinoma, thyroid cancer, and other solid tumours, with additional studies in glioma, neuroblastoma, and advanced hematologic malignancies.

  • Metastatic and advanced solid tumours
  • Genomically defined cancers
  • Breast, lung, prostate, and gastrointestinal cancers
  • Brain tumours and paediatric oncology

Research activity also covers tumour subtypes linked to KRAS, RET, FGFR3, IDH1, and IDH2 alterations.

Metabolic, Cardiovascular, and Renal Disorders

Studies focus on type 2 diabetes, type 1 diabetes, obesity, overweight, hypertension, atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, peripheral arterial disease, and chronic kidney disease.

  • Diabetes and beta-cell preservation
  • Weight management and obesity-related disease
  • Cardiovascular risk reduction
  • Kidney function and renal impairment

Additional interest includes lipoprotein(a) and broader lipid disorders in people at elevated cardiovascular risk.

Immunology, Inflammation, and Autoimmune Disease

The sponsor funds trials in rheumatoid arthritis, juvenile idiopathic arthritis, uveitis, atopic dermatitis, alopecia areata, hidradenitis suppurativa, Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases.

  • Inflammatory arthritis
  • Skin and hair autoimmune conditions
  • Ocular inflammation
  • Gastrointestinal immune-mediated disease

Research also extends to connective tissue diseases and immune system diseases across adult and paediatric populations.

Neurology, Neurodegeneration, and Migraine

Clinical programmes address Alzheimer disease, dementia, relapsing multiple sclerosis, sporadic amyotrophic lateral sclerosis, chronic migraine, and episodic migraine, alongside broader central nervous system diseases and neurocognitive disorders.

  • Alzheimer’s disease and cognitive decline
  • Multiple sclerosis
  • Motor neuron disease
  • Paediatric and adolescent migraine

Research interest includes disorders affecting the nervous system and neurodegenerative diseases across different stages of life.

Respiratory, Sleep, Pain, and Other Chronic Conditions

Additional studies cover asthma, chronic rhinosinusitis with nasal polyps, obstructive sleep apnea, osteoarthritis, chronic low back pain, neuropathic pain, stress urinary incontinence, nausea, and vomiting.

  • Airway and allergic disease
  • Sleep-disordered breathing
  • Musculoskeletal pain and joint disease
  • Urological symptoms and supportive care

Trial activity also includes chronic pain syndromes and other symptomatic conditions affecting daily function.

Sponsored Trials

Trial Name Country Status
A Phase 2 Study of LY4257496 in Participants with Advanced or Metastatic Solid Tumors Including Breast, Colorectal, Prostate, and Endometrial NeoplasmsGermany GermanyRecruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib and Fulvestrant in HR+, HER2- Advanced or Metastatic Breast Cancer Post-CDK4/6 Inhibitor TherapyBelgium BelgiumCzechia CzechiaDenmark DenmarkFrance FranceGreece GreeceHungary HungaryItaly ItalyPoland PolandSpain SpainNot Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Fulvestrant with or without Abemaciclib in HR+, HER2- Advanced Breast CancerBelgium BelgiumGreece GreeceItaly ItalyPoland PolandSpain SpainNot Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial of Orforglipron (LY3502970) for BMI Reduction in Adolescents with Obesity or Overweight-Related ComorbiditiesItaly ItalyPoland PolandRecruiting
A Randomized, Double‑Blind, Placebo‑Controlled Study of Eloralintide (LY3841136) in Adults With Overweight or ObesityGermany GermanySweden SwedenRecruiting
A Randomized, Double‑Blind, Placebo‑Controlled Study of LY4213663 in Healthy Volunteers and Adults with Rheumatoid ArthritisGermany GermanyNot Yet Recruiting
A Single-Dose Pharmacokinetic Study of Eloralintide in Subjects with Normal Hepatic Function and Varying Degrees of Hepatic ImpairmentHungary HungaryRecruiting
A Study of LY4175408 in Adults with Advanced or Metastatic Solid TumorsFrance FranceSpain SpainNot Recruiting
Baricitinib Versus TNF Inhibitors for Venous Thromboembolism Risk in Rheumatoid Arthritis: Phase 3b/4 Active-Controlled StudyAustria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyLithuania LithuaniaPoland PolandRomania RomaniaSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting
Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized TrialAustria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandRomania RomaniaSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Yet Recruiting
1–10 of 135
1 / 14

Data & Insights

science
Molecule Portfolio
Compounds under investigation
12
Exclusive Molecules
out of 19 total (63% not shared with other sponsors)

This sponsor works with 19 molecules, of which 12 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
43%
Return partnership rate
724 of 1693 sites collaborated multiple times

This sponsor has worked with 1693 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms41 trials
    856 other sponsors
  • 2.
    Nutritional and Metabolic Diseases31 trials
    220 other sponsors
  • 3.
    Immune System Diseases13 trials
    330 other sponsors
  • 4.
    Nervous System Diseases13 trials
    455 other sponsors
  • 5.
    Digestive System Diseases10 trials
    283 other sponsors
  • 6.
    Respiratory Tract Diseases7 trials
    280 other sponsors
  • 7.
    Cardiovascular Diseases6 trials
    365 other sponsors
  • 8.
    Skin and Connective Tissue Diseases5 trials
    251 other sponsors
  • 9.
    Musculoskeletal Diseases4 trials
    243 other sponsors
  • 10.
    Behavioral Disciplines and Activities2 trials
    21 other sponsors
  • 11.
    Metabolism2 trials
    39 other sponsors
  • 12.
    Otorhinolaryngologic Diseases2 trials
    50 other sponsors
  • 13.
    Female Urogenital Diseases and Pregnancy Complications1 trial
    148 other sponsors
  • 14.
    Hemic and Lymphatic Diseases1 trial
    254 other sponsors
  • 15.
    Hormonal diseases1 trial
    92 other sponsors
  • 16.
    Immune system processes1 trial
    68 other sponsors
  • 17.
    Mental Disorders1 trial
    153 other sponsors

Partnered Research Centres

1693 centres
location_city
assignment62
4 Wojskowy SzpitaKliniczny Z Polikliniką Samodzielny Publiczny ZakładOpieki ZdrowotneWe Wrocławiu
Address
Ul. Rudolfa Weigla 5, 53-114 Wroclaw
Learn morearrow_forward
location_city
assignment1
4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ
Address
ul. Rudolfa Weigla 5, 50-981 Wroclaw
Learn morearrow_forward
location_city
assignment11
424 Military General Training Hospital
Address
Ring Road, N. Efkarpia, 564 29 Thessaloniki
Learn morearrow_forward
location_city
assignment39
A-Shine s.r.o.
Address
Sumavska 2, Vychodni Predmesti, 301 00 Pilsen
Learn morearrow_forward
location_city
assignment23
A.O. Krankenhaus St. Josef Braunau GmbH
Address
Ringstrasse 60, 5280 Braunau am Inn
Learn morearrow_forward
location_city
assignment108
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
Page 1 of 283

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Eli Lilly & Co..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.